文献速递瓣膜外科

第三代猪源生物瓣二尖瓣置换的耐久性:单中心482例随访结果

Durability of Mitral Valve Replacement With a Third-generation Bioprosthesis.
PubMed 文献 · Ann Thorac Surg · 2021-04-23

术后8.8年总体生存率69.5%±5%,5年和10年免于结构性瓣膜衰败率(竞争风险)分别为97.8%±1%和91.9%±3.3%,按年龄分层无显著差异。结论认为该瓣膜在二尖瓣位置5—10年耐久性良好。

要点

  • Epic猪源生物瓣二尖瓣置换后10年免于结构性瓣膜衰败率(竞争风险)为91.9%±3.3%。
  • 按手术年龄≤59岁、60—69岁、≥70岁分层,免于结构性瓣膜衰败率无显著组间差异(log-rank P=.24)。
  • 10年免于任何因结构性瓣膜衰败的再干预率(竞争风险)为92.7%±3.3%,组间无差异(log-rank P=.14)。

核心结论

  • Epic第三代猪源生物瓣在二尖瓣位置5至10年耐久性良好。

主要发现

  • 手术死亡率为9.3%,早期瓣膜相关再手术5例,主要因复发性感染性心内膜炎。
  • 随访期间发生9例结构性瓣膜衰败(SVD),其中3例再手术、4例经导管二尖瓣瓣中瓣置换、2例仅药物治疗。
  • 8.8年总体生存率为69.5%±5%,8.4年免于任何瓣膜相关并发症率( actuarial)为83.2%±4.5%。

关键数值与推荐

  • 5年和10年免于SVD率: actuarial分别为97.4%±1.2%和89.6%±4.4%,竞争风险分别为97.8%±1%和91.9%±3.3%。
  • 按手术年龄分层(≤59岁50.8%、60—69岁32.8%、≥70岁16.4%),免于SVD率无显著组间差异(log-rank P=.24)。
  • 10年免于任何因SVD再干预率: actuarial为90.5%±4.4%,竞争风险为92.7%±3.3%,组间无差异(log-rank P=.14)。

临床怎么用

  • 对于二尖瓣置换患者,Epic猪源生物瓣可作为生物瓣选择之一,5—10年耐久性良好,且不同年龄组免于SVD率无显著差异。

局限性

  • 单中心回顾性设计,平均随访时间较短(3.8±2.5年),10年数据基于 actuarial 和竞争风险分析,需更长期随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Our aim was to evaluate the durability of a third-generation porcine bioprosthesis (Epic porcine xenograft; Abbott Cardiovascular Inc, St Paul, MN) in the mitral position, according to patients' age at surgery. METHODS: Four hundred eighty-two mitral valve replacements using the Epic valve at a single center were included (2009-2018). Perioperative and early postoperative data were prospectively collected. A systematic follow-up was performed (99% complete, 1609.5 patient-years; average, 3.8 ± 2.5). Standardized definitions of valve-related events were adopted. Mean patient age at mitral valve replacement was 68.1 ± 10.4 years. RESULTS: Operative mortality was 9.3%. There were 5 early valve-related reoperations, mainly due to recurrent infectious endocarditis. Global survival at 8.8 years was 69.5% ± 5%. Nine structural valve deterioration (SVD) events occurred during follow-up (3 receiving reoperations, 4 transcatheter mitral valve replacement valve-in-valve, and 2 medical treatment only). The freedom from SVD at 5 and 10 years was 97.4% ± 1.2% and 89.6% ± 4.4% (actuarial) and 97.8% ± 1% and 91.9% ± 3.3%, respectively (competing risks). After stratification into subgroups by age at surgery (≤59 years, 50.8%; 60-69, 32.8%; ≥70, 16.4%) there was no significant intergroup difference in freedom from SVD (log-rank P = .24). The overall freedom from any reintervention for SVD at 10 years was 90.5% ± 4.4% (actuarial) and 92.7% ± 3.3% (competing risks), with no intergroup difference (log-rank P = .14). The freedom from any valve-related complication at 8.4 years was 83.2% ± 4.5% (actuarial). CONCLUSIONS: The Epic bioprosthesis shows good durability at 5 to 10 years in the mitral position.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Anselmi A, Aymami M, Tomasi J, et al. Durability of Mitral Valve Replacement With a Third-generation Bioprosthesis. Ann Thorac Surg. 2021. PMID: 33901453. doi:10.1016/j.athoracsur.2021.03.097

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。